Long‐term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease
Authors:
- 7 January 2020
- journal article
- review article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 34 (6) , 1161-1173
Abstract
Psoriatic disease is a multifaceted disorder, which develops in the skin, its appendages and joints. Though characterized by different pathogenic background and clinical manifestations, skin plaque psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are related, sharing key inflammatory mechanisms and hence mode of management. Secukinumab is a fully human monoclonal antibody that selectively binds and neutralizes interleukin‐17A. It has been approved for use as a subcutaneous injection for the treatment of moderate‐to‐severe PsO, PsA and AS. The current review highlights the long‐term efficacy and safety profile of secukinumab in the treatment of plaque psoriasis and its multiple manifestations from its phase 3 clinical trial programme. The long‐term extension of pivotal trials has shown sustainable efficacy and safety of secukinumab up to 5 years in PsO, PsA and AS and up to 2.5 years in moderate‐to‐severe nail and palmoplantar PsO through dedicated randomized controlled trials. The effect of secukinumab therapy in all these indications has corresponding effects on improvement in quality‐of‐life and daily activities. Overall, secukinumab is an effective and safe treatment choice for patients suffering from psoriatic disease in its multiple clinical variants.Keywords
This publication has 91 references indexed in Scilit:
- Effect of IL-17A blockade with secukinumab in autoimmune diseasesAnnals of the Rheumatic Diseases, 2013
- IL-17A and IFN-γ Synergistically Induce RNase 7 Expression via STAT3 in Primary KeratinocytesPLOS ONE, 2013
- The role of IL-17-secreting mast cells in inflammatory joint diseaseNature Reviews Rheumatology, 2012
- Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serumExperimental Dermatology, 2011
- Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in PsoriasisThe Journal of Immunology, 2011
- Analysis of IL-17+cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune responseArthritis Research & Therapy, 2011
- Newer trends in the management of psoriasis at difficult to treat locations: Scalp, palmoplantar disease and nailsIndian Journal of Dermatology, Venereology and Leprology, 2010
- Psoriasis associated with ulcerative colitis and Crohn's diseaseJournal of the European Academy of Dermatology and Venereology, 2009
- Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: A population‐based studyArthritis Care & Research, 2009
- Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areasClinics in Dermatology, 2008